These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 22989076)
21. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology]. Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576 [TBL] [Abstract][Full Text] [Related]
22. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080 [TBL] [Abstract][Full Text] [Related]
23. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. Scaringi C; Minniti G; Caporello P; Enrici RM Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541 [TBL] [Abstract][Full Text] [Related]
24. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model. Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827 [TBL] [Abstract][Full Text] [Related]
25. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Yamada S; Bu XY; Khankaldyyan V; Gonzales-Gomez I; McComb JG; Laug WE Neurosurgery; 2006 Dec; 59(6):1304-12; discussion 1312. PubMed ID: 17277694 [TBL] [Abstract][Full Text] [Related]
26. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Reardon DA; Nabors LB; Stupp R; Mikkelsen T Expert Opin Investig Drugs; 2008 Aug; 17(8):1225-35. PubMed ID: 18616418 [TBL] [Abstract][Full Text] [Related]
27. IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Bello L; Lucini V; Giussani C; Carrabba G; Pluderi M; Scaglione F; Tomei G; Villani R; Black PM; Bikfalvi A; Carroll RS Neurosurgery; 2003 Jan; 52(1):177-85; discussion 185-6. PubMed ID: 12493116 [TBL] [Abstract][Full Text] [Related]
29. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930 [TBL] [Abstract][Full Text] [Related]
30. Acute Temporal Changes of MRI-Tracked Tumor Vascular Parameters after Combined Anti-angiogenic and Radiation Treatments in a Rat Glioma Model: Identifying Signatures of Synergism. Elmghirbi R; Nagaraja TN; Brown SL; Panda S; Aryal MP; Keenan KA; Bagher-Ebadian H; Cabral G; Ewing JR Radiat Res; 2017 Jan; 187(1):79-88. PubMed ID: 28001908 [TBL] [Abstract][Full Text] [Related]
31. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Colen CB; Shen Y; Ghoddoussi F; Yu P; Francis TB; Koch BJ; Monterey MD; Galloway MP; Sloan AE; Mathupala SP Neoplasia; 2011 Jul; 13(7):620-32. PubMed ID: 21750656 [TBL] [Abstract][Full Text] [Related]
32. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis. Bretschi M; Cheng C; Witt H; Dimitrakopoulou-Strauss A; Strauss LG; Semmler W; Bäuerle T J Cancer Res Clin Oncol; 2013 Apr; 139(4):573-83. PubMed ID: 23229276 [TBL] [Abstract][Full Text] [Related]
33. Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of glioma cells by inactivating Wnt/β-catenin signaling. Tao Q; Wu C; Xu R; Niu L; Qin J; Liu N; Zhang P; Wang C Cell Tissue Res; 2017 Dec; 370(3):379-390. PubMed ID: 28815294 [TBL] [Abstract][Full Text] [Related]
34. Novel Integrin αvβ3-Specific Ligand for the Sensitive Diagnosis of Glioblastoma. Zhang L; Shan X; Meng X; Gu T; Guo L; An X; Jiang Q; Ge H; Ning X Mol Pharm; 2019 Sep; 16(9):3977-3984. PubMed ID: 31306580 [TBL] [Abstract][Full Text] [Related]
35. Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery. Zhao YZ; Lin Q; Wong HL; Shen XT; Yang W; Xu HL; Mao KL; Tian FR; Yang JJ; Xu J; Xiao J; Lu CT J Control Release; 2016 Feb; 224():112-125. PubMed ID: 26792571 [TBL] [Abstract][Full Text] [Related]
36. Angiogenesis and invasion in glioma. Onishi M; Ichikawa T; Kurozumi K; Date I Brain Tumor Pathol; 2011 Feb; 28(1):13-24. PubMed ID: 21221826 [TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of the anti-glioma effect of Cilengitide. Onishi M; Kurozumi K; Ichikawa T; Michiue H; Fujii K; Ishida J; Shimazu Y; Chiocca EA; Kaur B; Date I Springerplus; 2013 Dec; 2(1):160. PubMed ID: 23667810 [TBL] [Abstract][Full Text] [Related]
38. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas. Li Y; Fu SY; Wang LH; Wang FY; Wang NN; Cao Q; Wang YT; Yang JY; Wu CF Cancer Lett; 2015 Dec; 369(1):86-96. PubMed ID: 26254539 [TBL] [Abstract][Full Text] [Related]
39. Alphaxalone inhibits growth, migration and invasion of rat C6 malignant glioma cells. Sun H; Zheng X; Zhou Y; Zhu W; Ou Y; Shu M; Gao X; Leng T; Qiu P; Yan G Steroids; 2013 Oct; 78(10):1041-5. PubMed ID: 23831782 [TBL] [Abstract][Full Text] [Related]
40. [Inhibiting cerebral glioma growth with continuous low-dose chemotherapy and cyclooxygenase-2 inhibitor in nude mice]. Sun JJ; Wang ZY; Liu B; Zhong YF; Du J; Chen YY; Ma CC; Chen XD Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 38(3):252-6. PubMed ID: 16778966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]